Emerging drug therapies in Huntington's disease

Bibliography

• Bates G, Harper P, Jones L. Huntington's disease. ed 3rd, Oxford, New York Oxford University Press (UK); 2002
   Google Scholar
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993;72:971-83
   PubMed Web of Science ®Google Scholar
• Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998;57:369-84
   PubMed Web of Science ®Google Scholar
• Rosas HD, Salat DH, Lee SY, et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008;131:1057-68
   PubMed Web of Science ®Google Scholar
• Aylward EH, Codori AM, Barta PE, et al. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 1996;53:1293-6
   PubMed Web of Science ®Google Scholar
• Halliday GM, McRitchie DA, Macdonald V, et al. Regional specificity of brain atrophy in Huntington's disease. Exp Neurol 1998;154:663-72
   PubMed Web of Science ®Google Scholar
• Spargo E, Everall IP, Lantos PL. Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection. J Neurol Neurosurg Psychiatry 1993;56:487-91
   PubMed Web of Science ®Google Scholar
• Heinsen H, Rub U, Bauer M, et al. Nerve cell loss in the thalamic mediodorsal nucleus in Huntington's disease. Acta Neuropathol 1999;97:613-22
   PubMed Web of Science ®Google Scholar
• Gil JM, Rego AC. Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 2008;27:2803-20
   PubMed Web of Science ®Google Scholar
• Leegwater-Kim J, Cha JH. The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration. NeuroRx 2004;1:128-38
   PubMedGoogle Scholar
• Martin JB, Gusella JF. Huntington's disease. Pathogenesis and management. N Engl J Med 1986;315:1267-76
   PubMed Web of Science ®Google Scholar
• Ikonen E, Ignatius J, Norio R, et al. Huntington disease in Finland: a molecular and genealogical study. Hum Genet 1992;89:275-80
   PubMed Web of Science ®Google Scholar
• Wexler NS, Lorimer J, Porter J, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci USA 2004;101:3498-503
   PubMed Web of Science ®Google Scholar
• Tibben A. Predictive testing for Huntington's disease. Brain Res Bull 2007;72:165-71
   PubMed Web of Science ®Google Scholar
• Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord 2008;23:1491-504
   PubMed Web of Science ®Google Scholar
• Kenney C, Powell S, Jankovic J. Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord 2007;22:127-30
   PubMed Web of Science ®Google Scholar
• Andrew SE, Goldberg YP, Kremer B, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 1993;4:398-403
   PubMed Web of Science ®Google Scholar
• Rubinsztein DC, Leggo J, Chiano M, et al. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. Proc Natl Acad Sci USA 1997;94:3872-6
   PubMed Web of Science ®Google Scholar
• Diguet E, Fernagut PO, Normand E, et al. Experimental basis for the putative role of GluR6/kainate glutamate receptor subunit in Huntington's disease natural history. Neurobiol Dis 2004;15:667-75
   PubMed Web of Science ®Google Scholar
• MacDonald ME, Vonsattel JP, Shrinidhi J, et al. Evidence for the GluR6 gene associated with younger onset age of Huntington's disease. Neurology 1999;53:1330-2
   PubMed Web of Science ®Google Scholar
• Paschen W, Hedreen JC, Ross CA. RNA editing of the glutamate receptor subunits GluR2 and GluR6 in human brain tissue. J Neurochem 1994;63:1596-602
   PubMed Web of Science ®Google Scholar
• Imarisio S, Carmichael J, Korolchuk V, et al. Huntington's disease: from pathology and genetics to potential therapies. Biochem J 2008;412:191-209
   PubMed Web of Science ®Google Scholar
• Kremer B. Clinical neurology of Huntington's disease. In: Bates GP, Harper P, Jones L, editors, Huntington's Disease. Oxford Monographs On Medical Genetics. Oxford: New York Oxford University Press (UK); 2002, volume 1
   Google Scholar
• Morton AJ, Wood NI, Hastings MH, et al. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J Neurosci 2005;25:157-63
   PubMed Web of Science ®Google Scholar
• Goodman AO, Murgatroyd PR, Medina-Gomez G, et al. The metabolic profile of early Huntington's disease–a combined human and transgenic mouse study. Exp Neurol 2008;210:691-8
   PubMed Web of Science ®Google Scholar
• Ho AK, Sahakian BJ, Brown RG, et al. Profile of cognitive progression in early Huntington's disease. Neurology 2003;61:1702-6
   PubMed Web of Science ®Google Scholar
• Solomon AC, Stout JC, Weaver M, et al. Ten-year rate of longitudinal change in neurocognitive and motor function in prediagnosis Huntington disease. Mov Disord 2008;23:1830-6
   PubMed Web of Science ®Google Scholar
• van Duijn E, Kingma EM, van der Mast RC. Psychopathology in verified Huntington's disease gene carriers. J Neuropsychiatry Clin Neurosci 2007;19:441-8
   PubMed Web of Science ®Google Scholar
• Schoenfeld M, Myers RH, Cupples LA, et al. Increased rate of suicide among patients with Huntington's disease. J Neurol Neurosurg Psychiatry 1984;47:1283-7
   PubMed Web of Science ®Google Scholar
• Zappacosta B, Monza D, Meoni C, et al. Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington's disease. Arch Neurol 1996;53:493-7
   PubMed Web of Science ®Google Scholar
• Clelland CD, Barker RA, Watts C. Cell therapy in Huntington disease. Neurosurg Focus 2008;24:E9
   PubMed Web of Science ®Google Scholar
• Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 1996;11:136-42
   PubMed Web of Science ®Google Scholar
• Wild EJ, Tabrizi SJ. The differential diagnosis of chorea. Pract Neurol 2007;7:360-73
   PubMedGoogle Scholar
• Paulsen JS, Hayden M, Stout JC, et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 2006;63:883-90
   PubMed Web of Science ®Google Scholar
• Lawrence AD, Hodges JR, Rosser AE, et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 1998;121(Pt 7):1329-41
   PubMed Web of Science ®Google Scholar
• Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics 2008;5:181-97
   PubMed Web of Science ®Google Scholar
• Priller J, Ecker D, Landwehrmeyer B, Craufurd D. A Europe-wide assessment of current medication choices in Huntington's disease. Mov Disord 2008;23:1788
   PubMed Web of Science ®Google Scholar
• Medivation I. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease. In, Huntington's Stud Group Website, 2008
   Google Scholar
• Roze E, Saudou F, Caboche J. Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr Opin Neurol 2008;21:497-503
   PubMed Web of Science ®Google Scholar
• Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991;4:109-20
   PubMed Web of Science ®Google Scholar
• Grohmann R, Koch R, Schmidt LG. Extrapyramidal symptoms in neuroleptic recipients. Agents Actions Suppl 1990;29:71-82
   PubMedGoogle Scholar
• Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007;13:13-24
   PubMedGoogle Scholar
• Koller WC, Trimble J. The gait abnormality of Huntington's disease. Neurology 1985;35:1450-4
   PubMed Web of Science ®Google Scholar
• Gimenez-Roldan S, Mateo D. Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements. Neurologia 1989;4:282-7
   PubMedGoogle Scholar
• Barr AN, Fischer JH, Koller WC, et al. Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology 1988;38:84-8
   PubMed Web of Science ®Google Scholar
• Saran BM, Klein MS, Benay EM. Clinical evaluation of amantadine and haloperidol in Huntington's chorea. J Clin Psychiatry 1980;41:221
   PubMed Web of Science ®Google Scholar
• Leonard DP, Kidson MA, Brown JG, et al. A double blind trial of lithium carbonate and haloperidol in Huntington's chorea. Aust NZ J Psychiatry 1975;9:115-8
   PubMed Web of Science ®Google Scholar
• Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry 1984;47:844-7
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 2006;12:2701-20
   PubMed Web of Science ®Google Scholar
• Squitieri F, Cannella M, Piorcellini A, et al. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:69-72
   PubMedGoogle Scholar
• Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. Acta Neurol Scand 2002;105:441-4
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Niederwieser G, Tribl GG, Koltringer P. High-dose olanzapine in Huntington's disease. Int Clin Psychopharmacol 2002;17:91-3
   PubMed Web of Science ®Google Scholar
• Grove VE Jr, Quintanilla J, DeVaney GT. Improvement of Huntington's disease with olanzapine and valproate. N Engl J Med 2000;343:973-4
   PubMed Web of Science ®Google Scholar
• Benazzi F. Rapid onset of tardive dyskinesia in Huntington disease with olanzapine. J Clin Psychopharmacol 2002;22:438-9
   PubMed Web of Science ®Google Scholar
• Albanese A, Cassetta E, Carretta D, et al. Acute challenge with apomorphine in Huntington's disease: a double-blind study. Clin Neuropharmacol 1995;18:427-34
   PubMed Web of Science ®Google Scholar
• Corsini GU, Onali P, Masala C, et al. Apomorphine hydrochloride-induced improvement in Huntington's chorea: stimulation of dopamine receptor. Arch Neurol 1978;35:27-30
   PubMed Web of Science ®Google Scholar
• Vitale C, Marconi S, Di Maio L, et al. Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: a double blind, randomized cross-over trial. Mov Disord 2007;22:2359-64
   PubMed Web of Science ®Google Scholar
• Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington's disease. J Neurol Neurosurg Psychiatry 1998;65:577-9
   PubMed Web of Science ®Google Scholar
• Jongen PJ, Renier WO, Gabreels FJ. Seven cases of Huntington's disease in childhood and levodopa induced improvement in the hypokinetic–rigid form. Clin Neurol Neurosurg 1980;82:251-61
   PubMed Web of Science ®Google Scholar
• Low PA, Allsop JL, Halmagyi GM. Huntington's chorea: the rigid form (Westphal variant) treated with levodopa. Med J Aust 1974;1:393-4
   PubMed Web of Science ®Google Scholar
• Reuter I, Hu MT, Andrews TC, et al. Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome. J Neurol Neurosurg Psychiatry 2000;68:238-41
   PubMed Web of Science ®Google Scholar
• Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988;38:391-4
   PubMed Web of Science ®Google Scholar
• Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-72
   PubMed Web of Science ®Google Scholar
• Frank S, Ondo W, Fahn S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 2008;31:127-33
   PubMed Web of Science ®Google Scholar
• Brusa L, Orlacchio A, Moschella V, et al. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009;24:126-9
   PubMed Web of Science ®Google Scholar
• Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-62
   PubMed Web of Science ®Google Scholar
• Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22:193-7
   PubMed Web of Science ®Google Scholar
• Fasano A, Cadeddu F, Guidubaldi A, et al. The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol 2008;31:313-8
   PubMed Web of Science ®Google Scholar
• Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 1982;11:41-7
   PubMed Web of Science ®Google Scholar
• Hayden MR, Leavitt BR, Yasothan U, Kirkpatrick P. Tetrabenazine. Nat Rev Drug Discov 2009;8:17-8
   PubMed Web of Science ®Google Scholar
• Levine MS, Klapstein GJ, Koppel A, et al. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 1999;58:515-32
   PubMed Web of Science ®Google Scholar
• Cepeda C, Hurst RS, Altemus KL, et al. Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J Neurophysiol 2001;85:659-70
   PubMed Web of Science ®Google Scholar
• Verhagen Metman L, Morris MJ, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002;59:694-9
   PubMed Web of Science ®Google Scholar
• O'Suilleabhain P, Dewey RB Jr. A randomized trial of amantadine in Huntington disease. Arch Neurol 2003;60:996-8
   PubMed Web of Science ®Google Scholar
• Stewart JT. Adverse behavioral effects of amantadine therapy in Huntington's disease. South Med J 1987;80:1324-5
   PubMed Web of Science ®Google Scholar
• Beister A, Kraus P, Kuhn W, et al. The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. J Neural Transm Suppl 2004;68:117-22
   PubMed Web of Science ®Google Scholar
• Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord 2007;13:453-4
   PubMed Web of Science ®Google Scholar
• Giuffra ME, Mouradian MM, Chase TN. Glutamatergic therapy of Huntington's chorea. Clin Neuropharmacol 1992;15:148-51
   PubMed Web of Science ®Google Scholar
• Murman DL, Giordani B, Mellow AM, et al. Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease. Neurology 1997;49:153-61
   PubMed Web of Science ®Google Scholar
• Shoulson I, Goldblatt D, Charlton M, Joynt RJ. Huntington's disease: treatment with muscimol, a GABA-mimetic drug. Ann Neurol 1978;4:279-84
   PubMed Web of Science ®Google Scholar
• Perry TL, Wright JM, Hansen S, et al. Failure of aminooxyacetic acid therapy in Huntington disease. Neurology 1980;30:772-5
   PubMed Web of Science ®Google Scholar
• Manyam BV, Ferraro TN, Hare TA. Isoniazid-induced alteration of CSF neurotransmitter amino acids in Huntington's disease. Brain Res 1987;408:125-30
   PubMed Web of Science ®Google Scholar
• Anden NE, Dalen P, Johansson B. Baclofen and lithium in Huntington's chorea. Lancet 1973;2:93
   PubMed Web of Science ®Google Scholar
• Paulson GW. Lioresal in Huntington's disease. Dis Nerv Syst 1976;37:465-7
   PubMedGoogle Scholar
• Shoulson I, Odoroff C, Oakes D, et al. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol 1989;25:252-9
   PubMed Web of Science ®Google Scholar
• Yohrling G, Cha JH. Neurochemistry of Huntington's disease. In: Bates GP, Harper P, Jones L, editors, Huntington's disease. Oxford Monographs On Medical Genetics. Oxford: New York Oxford University Press (UK); 2002, volume 1
   Google Scholar
• Reisine TD, Wastek GJ, Speth RC, et al. Alterations in the benzodiazepine receptor of Huntington's diseased human brain. Brain Res 1979;165:183-7
   PubMed Web of Science ®Google Scholar
• Peiris JB, Boralessa H, Lionel ND. Clonazepam in the treatment of choreiform activity. Med J Aust 1976;1:225-7
   PubMed Web of Science ®Google Scholar
• Stewart JT. Treatment of Huntington's disease with clonazepam. South Med J 1988;81:102
   PubMed Web of Science ®Google Scholar
• Farrell DF, Hofmann WW. A quantitative evaluation of the effect of diazepam in Huntington's chorea. Arch Phys Med Rehabil 1968;49:586-91
   PubMedGoogle Scholar
• de Tommaso M, Difruscolo O, Sciruicchio V, et al. Two years' follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol 2007;30:43-6
   PubMed Web of Science ®Google Scholar
• Cubo E, Shannon KM, Tracy D, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology 2006;67:1268-71
   PubMed Web of Science ®Google Scholar
• Ready RE, Mathews M, Leserman A, Paulsen JS. Patient and caregiver quality of life in Huntington's disease. Mov Disord 2008;23:721-6
   PubMed Web of Science ®Google Scholar
• Paulsen JS, Ready RE, Hamilton JM, et al. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry 2001;71:310-4
   PubMed Web of Science ®Google Scholar
• Bonelli RM. Mirtazapine in suicidal Huntington's disease. Ann Pharmacother 2003;37:452
   PubMed Web of Science ®Google Scholar
• Patel SV, Tariot PN, Asnis J. L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease. Ann Clin Psychiatry 1996;8:23-6
   PubMedGoogle Scholar
• Ford MF. Treatment of depression in Huntington's disease with monoamine oxidase inhibitors. Br J Psychiatry 1986;149:654-6
   PubMed Web of Science ®Google Scholar
• Candelise L. Haloperidol, reserpine, l-dopa and amantidine in the treatment of Huntington chorea (author's transl). Riv Patol Nerv Ment 1976;96:54-62
   PubMedGoogle Scholar
• Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol 1999;19:101-3
   PubMed Web of Science ®Google Scholar
• Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease. Psychosomatics 2006;47:70-2
   PubMed Web of Science ®Google Scholar
• Goutopoulos A, Makriyannis A. From cannabis to cannabinergics: new therapeutic opportunities. Pharmacol Ther 2002;95:103-17
   PubMed Web of Science ®Google Scholar
• Curtis A, Rickards H. Nabilone could treat chorea and irritability in Huntington's disease. J Neuropsychiatry Clin Neurosci 2006;18:553-4
   PubMed Web of Science ®Google Scholar
• Kingma EM, van Duijn E, Timman R, et al. Behavioural problems in Huntington's disease using the problem behaviours assessment. Gen Hosp Psychiatry 2008;30:155-61
   PubMed Web of Science ®Google Scholar
• Hamilton JM, Salmon DP, Corey-Bloom J, et al. Behavioural abnormalities contribute to functional decline in Huntington's disease. J Neurol Neurosurg Psychiatry 2003;74:120-2
   PubMed Web of Science ®Google Scholar
• Snowden JS, Craufurd D, Griffiths HL, Neary D. Awareness of involuntary movements in Huntington disease. Arch Neurol 1998;55:801-5
   PubMed Web of Science ®Google Scholar
• Ho AK, Gilbert AS, Mason SL, et al. Goodman AO, Barker RA: Health-related quality of life in Huntington's disease: which factors matter most? Mov Disord 2008;24(4):572-6
   Google Scholar
• Nasir J, Floresco SB, O'Kusky JR, et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995;81:811-23
   PubMed Web of Science ®Google Scholar
• Nellemann C, Abell K, Norremolle A, et al. Inhibition of Huntington synthesis by antisense oligodeoxynucleotides. Mol Cell Neurosci 2000;16:313-23
   PubMed Web of Science ®Google Scholar
• Yen L, Strittmatter SM, Kalb RG. Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA. Ann Neurol 1999;46:366-73
   PubMed Web of Science ®Google Scholar
• Dunah AW, Jeong H, Griffin A, et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002;296:2238-43
   PubMed Web of Science ®Google Scholar
• Steffan JS, Kazantsev A, Spasic-Boskovic O, et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 2000;97:6763-8
   PubMed Web of Science ®Google Scholar
• Jiang H, Poirier MA, Liang Y, et al. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. Neurobiol Dis 2006;23:543-51
   PubMed Web of Science ®Google Scholar
• Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001;413:739-43
   PubMed Web of Science ®Google Scholar
• Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003;23:9418-27
   PubMed Web of Science ®Google Scholar
• Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003;100:2041-6
   PubMed Web of Science ®Google Scholar
• Gardian G, Browne SE, Choi DK, et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 2005;280:556-63
   PubMed Web of Science ®Google Scholar
• Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797-801
   PubMed Web of Science ®Google Scholar
• Ryu JK, McLarnon JG. Minocycline or iNOS inhibition block 3-nitrotyrosine increases and blood-brain barrier leakiness in amyloid beta-peptide-injected rat hippocampus. Exp Neurol 2006;198:552-7
   PubMed Web of Science ®Google Scholar
• Smith DL, Woodman B, Mahal A, et al. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 2003;54:186-96
   PubMed Web of Science ®Google Scholar
• Minocycline safety and tolerability in Huntington disease. Neurology 2004;63:547-9
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Heuberger C, Reisecker F. Minocycline for Huntington's disease: an open label study. Neurology 2003;60:883-4
   PubMed Web of Science ®Google Scholar
• Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov Disord 2004;19:692-5
   PubMed Web of Science ®Google Scholar
• Tanaka M, Machida Y, Niu S, et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 2004;10:148-54
   PubMed Web of Science ®Google Scholar
• Katsuno M, Adachi H, Sobue G. Sweet relief for Huntington disease. Nat Med 2004;10:123-4
   PubMed Web of Science ®Google Scholar
• Tanaka K, Shouguchi-Miyata J, Miyamoto N, Ikeda JE. Novel nuclear shuttle proteins, HDBP1 and HDBP2, bind to neuronal cell-specific cis-regulatory element in the promoter for the human Huntington's disease gene. J Biol Chem 2004;279:7275-86
   PubMed Web of Science ®Google Scholar
• Valera AG, Diaz-Hernandez M, Hernandez F, et al. The ubiquitin-proteasome system in Huntington's disease. Neuroscientist 2005;11:583-94
   PubMed Web of Science ®Google Scholar
• Ravikumar B, Rubinsztein DC. Role of autophagy in the clearance of mutant huntingtin: a step towards therapy? Mol Aspects Med 2006;27:520-7
   PubMedGoogle Scholar
• Ayalon L, Doron R, Weiner I, Joel D. Amelioration of behavioral deficits in a rat model of Huntington's disease by an excitotoxic lesion to the globus pallidus. Exp Neurol 2004;186:46-58
   PubMed Web of Science ®Google Scholar
• Lacey CJ, Boyes J, Gerlach O, et al. GABA(B) receptors at glutamatergic synapses in the rat striatum. Neuroscience 2005;136:1083-95
   PubMed Web of Science ®Google Scholar
• Calabresi P, Mercuri NB, Stefani A, Bernardi G. Synaptic and intrinsic control of membrane excitability of neostriatal neurons. I. An in vivo analysis. J Neurophysiol 1990;63:651-62
   PubMed Web of Science ®Google Scholar
• Centonze D, Rossi S, Prosperetti C, et al. Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice. Biol Psychiatry 2005;57:1583-9
   PubMed Web of Science ®Google Scholar
• Dunnett SB, Rosser AE. Stem cell transplantation for Huntington's disease. Exp Neurol 2007;203:279-92
   PubMed Web of Science ®Google Scholar
• Rosser AE, Barker RA, Harrower T, et al. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatry 2002;73:678-85
   PubMed Web of Science ®Google Scholar
• Kopyov OV, Jacques S, Lieberman A, et al. Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp Neurol 1998;149:97-108
   PubMed Web of Science ®Google Scholar
• Bachoud-Levi A, Bourdet C, Brugieres P, et al. Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease. Exp Neurol 2000;161:194-202
   PubMed Web of Science ®Google Scholar
• Bachoud-Levi AC, Remy P, Nguyen JP, et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000;356:1975-9
   PubMed Web of Science ®Google Scholar
• Bachoud-Levi AC, Gaura V, Brugieres P, et al. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 2006;5:303-9
   PubMed Web of Science ®Google Scholar
• Hauser RA, Furtado S, Cimino CR, et al. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 2002;58:687-95
   PubMed Web of Science ®Google Scholar
• Lescaudron L, Unni D, Dunbar GL. Autologous adult bone marrow stem cell transplantation in an animal model of huntington's disease: behavioral and morphological outcomes. Int J Neurosci 2003;113:945-56
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Shannon KM, Kordower JH. Huntington's disease: pathological mechanisms and therapeutic strategies. Cell Transplant 2007;16:301-12
   PubMed Web of Science ®Google Scholar
• Emerich DF, Cain CK, Greco C, et al. Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's disease. Cell Transplant 1997;6:249-66
   PubMed Web of Science ®Google Scholar
• Emerich DF, Winn SR, Hantraye PM, et al. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 1997;386:395-9
   PubMed Web of Science ®Google Scholar
• Bloch J, Bachoud-Levi AC, Deglon N, et al. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 2004;15:968-75
   PubMed Web of Science ®Google Scholar
• Hockly E, Cordery PM, Woodman B, et al. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann Neurol 2002;51:235-42
   PubMed Web of Science ®Google Scholar
• van Dellen A, Hannan AJ. Genetic and environmental factors in the pathogenesis of Huntington's disease. Neurogenetics 2004;5:9-17
   PubMed Web of Science ®Google Scholar
• van Praag H, Kempermann G, Gage FH. Neural consequences of environmental enrichment. Nat Rev Neurosci 2000;1:191-8
   PubMed Web of Science ®Google Scholar
• Lazic SE, Grote HE, Blakemore C, et al. Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur J Neurosci 2006;23:1829-38
   PubMed Web of Science ®Google Scholar
• Spires TL, Grote HE, Varshney NK, et al. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J Neurosci 2004;24:2270-6
   PubMed Web of Science ®Google Scholar
• Young D, Lawlor PA, Leone P, et al. Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective. Nat Med 1999;5:448-53
   PubMed Web of Science ®Google Scholar
• Singhrao SK, Thomas P, Wood JD, et al. Huntingtin protein colocalizes with lesions of neurodegenerative diseases: an investigation in Huntington's, Alzheimer's, and Pick's diseases. Exp Neurol 1998;150:213-22
   PubMed Web of Science ®Google Scholar
• Valenzuela MJ. Brain reserve and the prevention of dementia. Curr Opin Psychiatry 2008;21:296-302
   PubMed Web of Science ®Google Scholar
• Georgiou N, Bradshaw JL, Chiu E, et al. Differential clinical and motor control function in a pair of monozygotic twins with Huntington's disease. Mov Disord 1999;14:320-5
   PubMed Web of Science ®Google Scholar
• Churchyard A. Lifestyle activity and age of onset in Huntington's disease. In: Huntington Disease Clinical Research Symposium. St Pete Beach, Florida, Huntington's Study Group: 2008
   Google Scholar
• Vonsattel JP, Keller C, Pilar Amaya MD. Neuropathology of Huntington's disease. Handb Clin Neurol 2008;89:599-618
   PubMedGoogle Scholar
• Hersch SM, Ferrante RJ. Translating therapies for Huntington's disease from genetic animal models to clinical trials. NeuroRx 2004;1:298-306
   PubMedGoogle Scholar
• Ferrante RJ, Ryu H, Kubilus JK, et al. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J Neurosci 2004;24:10335-42
   PubMed Web of Science ®Google Scholar
• Jones DE Jr, Cui DM, Miller DM. Expression of beta-galactosidase under the control of the human c-myc promoter in transgenic mice is inhibited by mithramycin. Oncogene 1995;10:2323-30
   PubMed Web of Science ®Google Scholar
• Minamiyama M, Katsuno M, Adachi H, et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2004;13:1183-92
   PubMed Web of Science ®Google Scholar
• Hogarth P, Lovrecic L, Krainc D. Sodium phenylbutyrate in Huntington's disease: a dose-finding study. Mov Disord 2007;22:1962-4
   PubMed Web of Science ®Google Scholar
• Keene CD, Rodrigues CM, Eich T, et al. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci USA 2002;99:10671-6
   PubMed Web of Science ®Google Scholar
• Keene CD, Rodrigues CM, Eich T, et al. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp Neurol 2001;171:351-60
   PubMed Web of Science ®Google Scholar
• Wood NI, Morton AJ. Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. Brain Res Bull 2003;61:375-83
   PubMed Web of Science ®Google Scholar
• Aminoff MJ, Marshall J. Treatment of Huntington's chorea with lithium carbonate. A double-blind trial. Lancet 1974;1:107-9
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Baastrup PC, Petersson H. Lithium treatment of Huntington's chorea. A placebo-controlled clinical trial. Acta Psychiatr Scand 1977;56:183-8
   PubMed Web of Science ®Google Scholar
• Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004;36:585-95
   PubMed Web of Science ®Google Scholar
• Karpuj MV, Becher MW, Springer JE, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 2002;8:143-9
   PubMed Web of Science ®Google Scholar
• Dedeoglu A, Kubilus JK, Jeitner TM, et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 2002;22:8942-50
   PubMed Web of Science ®Google Scholar
• Fox JH, Barber DS, Singh B, et al. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J Neurochem 2004;91:413-22
   PubMed Web of Science ®Google Scholar
• Shults C, Steardo L, Barone P, et al. Huntington's disease: effect of cysteamine, a somatostatin-depleting agent. Neurology 1986;36:1099-102
   PubMed Web of Science ®Google Scholar
• Dubinsky R, Gray C. CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. Mov Disord 2006;21:530-3
   PubMed Web of Science ®Google Scholar
• Clifford JJ, Drago J, Natoli AL, et al. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience 2002;109:81-8
   PubMed Web of Science ®Google Scholar
• Vaddadi KS, Soosai E, Chiu E, Dingjan P. A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. Neuroreport 2002;13:29-33
   PubMed Web of Science ®Google Scholar
• Puri BK, Bydder GM, Counsell SJ, et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 2002;13:123-6
   PubMed Web of Science ®Google Scholar
• Puri BK, Bydder GM, Manku MS, et al. Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington's disease. J Int Med Res 2008;36:896-905
   PubMed Web of Science ®Google Scholar
• Puri BK, Leavitt BR, Hayden MR, et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005;65:286-92
   PubMed Web of Science ®Google Scholar
• Randomized Controlled Trial of Ethyl-Eicosapentaenoic Acid in Huntington disease: The TREND-HD Study. Arch Neurol 2008;65:1582-9
   PubMed Web of Science ®Google Scholar
• Rosas HD, Koroshetz WJ, Jenkins BG, et al. Riluzole therapy in Huntington's disease (HD). Mov Disord 1999;14:326-30
   PubMed Web of Science ®Google Scholar
• Seppi K, Mueller J, Bodner T, et al. Riluzole in Huntington's disease (HD): an open label study with one year follow up. J Neurol 2001;248:866-9
   PubMed Web of Science ®Google Scholar
• Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 2003;61:1551-6
   PubMed Web of Science ®Google Scholar
• Landwehrmeyer GB, Dubois B, de Yebenes JG, et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007;62:262-72
   PubMed Web of Science ®Google Scholar
• Kieburtz K, Feigin A, McDermott M, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord 1996;11:273-7
   PubMed Web of Science ®Google Scholar
• A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Ferrante RJ, Gardian G, et al. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. J Neurochem 2003;86:267-72
   PubMed Web of Science ®Google Scholar
• Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. The Huntington Study Group. Neurology 1998;50:1366-73
   PubMed Web of Science ®Google Scholar
• Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008;372:207-15
   PubMed Web of Science ®Google Scholar
• Available from: https://www.euro-hd.net
   Google Scholar
• Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000;20:4389-97
   PubMed Web of Science ®Google Scholar
• Dedeoglu A, Kubilus JK, Yang L, et al. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem 2003;85:1359-67
   PubMed Web of Science ®Google Scholar
• Verbessem P, Lemiere J, Eijnde BO, et al. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 2003;61:925-30
   PubMed Web of Science ®Google Scholar
• Schilling G, Coonfield ML, Ross CA, Borchelt DR. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett 2001;315:149-53
   PubMed Web of Science ®Google Scholar
• Smith KM, Matson S, Matson WR, et al. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim Biophys Acta 2006;1762:616-26
   PubMed Web of Science ®Google Scholar
• Ferrante RJ, Andreassen OA, Dedeoglu A, et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 2002;22:1592-9
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk JM, Pearson J, Bailey CD, et al. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem 2005;95:210-20
   PubMed Web of Science ®Google Scholar
• Andreassen OA, Ferrante RJ, Huang HM, et al. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann Neurol 2001;50:112-7
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk JM, Pearson J, Rogers DA, et al. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol 2005;196:266-72
   PubMed Web of Science ®Google Scholar
• Duan W, Guo Z, Jiang H, et al. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol 2004;55:590-4
   PubMed Web of Science ®Google Scholar
• Schilling G, Savonenko AV, Klevytska A, et al. Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice. Hum Mol Genet 2004;13:1599-610
   PubMed Web of Science ®Google Scholar
• Hockly E, Tse J, Barker AL, et al. Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease. Neurobiol Dis 2006;21:228-36
   PubMed Web of Science ®Google Scholar
• Stack EC, Smith KM, Ryu H, et al. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta 2006;1762:373-80
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Blamire AM, Manners DN, et al. Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. Neurology 2003;61:141-2
   PubMed Web of Science ®Google Scholar